Published Date:2025-10-03 Original Link:https://www.onenessbio.com/en/news_detail385_1.htm No 1 Date of announcement 2025/10/03 Time of announcement 17:06:49 Subject The medical device registration application of Bonvadis for all indications in wounds has been accepted by ThaiFDA. To which item it meets Subparagraph 10 Date of events 2025/10/03 Statement Date of occurrence of the event：2025/10/03 New drug name or...Read More
Published Date:2025-10-03 Original Link:https://www.onenessbio.com/en/news_detail386_1.htm No 2 Date of announcement 2025/10/03 Time of announcement 17:20:21 Subject The medical device registration application of Bonvadis for all indications of wounds has been accepted by COFEPRIS in Mexico. To which item it meets Subparagraph 10 Date of events 2025/10/03 Statement 1. Date of occurrence of the event:2025/10/03...Read More
Published Date:2025-09-17 Original Link:https://www.onenessbio.com/en/news_detail387_1.htm No 1 Date of announcement 2025/09/17 Time of announcement 15:55:15 Subject A Thailand patent on the Anti-CεmX (FB825) antibody was granted To which item it meets Subparagraph 53 Date of events 2025/09/17 Statement 1.Date of occurrence of the event:2025/09/17 2.Company name:ONENESS BIOTECH CO., LTD 3.Relationship to the Company (please...Read More
Published Date:2025-08-29 Original Link:https://www.onenessbio.com/en/news_detail382_1.htm No 1 Date of announcement 2025/08/29 Time of announcement 15:34:49 Subject A U.S. patent titled ”METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTS” has been granted. To which item it meets Subparagraph 53 Date of events 2025/08/29 Statement 1.Date of occurrence of the event:2025/08/29 2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to...Read More
Published Date:2025-08-28 Original Link:https://www.onenessbio.com/en/news_detail380_1.htm No 1 Date of announcement 2025/08/28 Time of announcement 19:28:08 Subject Oneness has decided to discontinue the development of OB318 based on considerations of research and development efficiency. To which item it meets Subparagraph 10 Date of events 2025/08/28 Statement 1.Date of occurrence of the event: 2025/08/28 2.New drug name or...Read More
Published Date:2025-08-08 Original Link:https://www.onenessbio.com/en/news_detail381_1.htm No 1 Date of announcement 2025/08/08 Time of announcement 16:18:55 Subject The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors To which item it meets paragraph 31 Date of events 2025/08/08 Statement Date of the board of directors submitted or approved: 2025/08/08 Date of the audit...Read More
Published Date:2025-07-28 Original Link:https://www.onenessbio.com/en/news_detail384_1.htm No 1 Date of announcement 2025/07/28 Time of announcement 17:13:28 Subject The medical device registration application of Bonvadis for all indications in wounds has been accepted by Morocco AMMPS. To which item it meets Subparagraph 10 Date of events 2025/07/28 Statement 1. Date of occurrence of the event:2025/07/28 2. New drug...Read More
Published Date:2025-07-18 Original Link:https://www.onenessbio.com/en/news_detail373_1.htm No 1 Date of announcement 2025/07/18 Time of announcement 17:49:03 Subject Fespixon, the new drug in treatment of diabetic foot ulcers has been approved by Indonesia BPOM and the drug license has been granted. To which item it meets Subparagraph 10 Date of events 2025/07/18 Statement 1.Date of occurrence of the...Read More
Published Date:2025-06-10 Original Link:https://www.onenessbio.com/en/news_detail361_1.htm No 1 Date of announcement 2025/06/10 Time of announcement 19:25:42 Subject Today, Bonvadis is 510(k) cleared by the U.S. FDA for full-thickness chronic wounds, marking a significant milestone in international commercialization. To which item it meets Subparagraph 10 Date of events 2025/06/10 Statement 1. Date of occurrence of the event:2025/06/10...Read More
